{"analyses":[{"groupDescription":"Differences in rugae, pallor, petechiae, mucosal thinning and dryness between baseline and week 12","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Significant at p\\<0.05","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"groupDescription":"Differences in rugae, pallor, mucosal thinning, and dryness from baseline to 12 weeks","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Significant at p\\<0.05","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"groupDescription":"Difference in petechiae between baseline and week 12","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0061","pValueComment":"Significant at p\\<0.05","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.80","value":"-1.03"},{"groupId":"OG001","spread":"0.84","value":"-0.71"}]}],"title":"Rugae"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.84","value":"-0.88"},{"groupId":"OG001","spread":"0.75","value":"-0.91"}]}],"title":"Pallor"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.07","value":"-1.0"},{"groupId":"OG001","spread":"1.38","value":"-0.74"}]}],"title":"Petechiae"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.49","value":"-0.62"},{"groupId":"OG001","spread":"0.64","value":"-0.88"}]}],"title":"Mucosal thinning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.80","value":"-1.03"},{"groupId":"OG001","spread":"0.91","value":"-0.71"}]}],"title":"Dryness"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"During a gynecologic exam, the vaginal epithelium was assessed by an examiner using the Vaginal Atrophy Scoring Scale to evaluate Rugae (lack of), Pallor (pinkness), Petechiae, Mucosal thinning, Dryness. Scores range from 0 (none) to 3 (severe); higher scores indicate less favorable outcomes.","dispersionType":"Standard Deviation","groups":[{"description":"Estring 2mg ring inserted vaginally once every 12 weeks","id":"OG000","title":"Estring"},{"description":"Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment","id":"OG001","title":"Testosterone Cream"}],"paramType":"MEAN","populationDescription":"Patients with both baseline and week 12 gynecologic exams for evaluation of vaginal atrophy","reportingStatus":"POSTED","timeFrame":"Baseline, 12 weeks","title":"Change in Vaginal Epithelium Scores","type":"SECONDARY","unitOfMeasure":"units on a scale"}